Seeking Alpha·Sep 10, 2026
Solid Biosciences Inc. (SLDB) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSolid Biosciences Inc. (SLDB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Solid Biosciences is a pre-revenue gene therapy developer pivoting to SGT-003 for Duchenne muscular dystrophy, with R&D spending up 134% since 2024Q1 to $44.3M in 2026Q2. The intensified clinical investment has driven operating losses to -$57.4M quarterly, whi...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.38+17.8% vs -$0.46 | — vs — |
Q2 2026 May 12, 2026 | -$0.52-30.0% vs -$0.40 | — vs — |
Q2 2026 Mar 19, 2026 | -$0.50+2.0% vs -$0.51 | — vs — |
Q4 2025 Nov 3, 2025 | -$0.48-14.3% vs -$0.42 | — vs — |
Solid Biosciences Inc. (SLDB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
CHARLESTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: 2026 Cantor Global Healthcare Conference Bo Cumbo, President and CEO, and Gabriel Books, M.D.
Solid Biosciences is transitioning from a speculative Duchenne gene therapy play to a multi-asset rare disease platform with clinical validation momentum. SLDB's $380.7M cash position funds operations into 2028, supporting high-cost Phase 3 SGT-003 trials and multiple pipeline programs without near-term dilution risk. SGT-003's Phase 1/2 data show strong microdystrophin expression and safety, while additional programs in Friedreich's ataxia and CPVT expand addressable markets.
Benchmark SLDB against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Solid Biosciences Inc. (SLDB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $8.02 | $789.57M | -4.03 | — | — | -109.9% | — | |
| $18.95 | $2B | -2.66 | 15.58% | -6.93% | -9.96% | — | |
| $55.76 | $5.38B | -8.62 | -89.97% | -3368.72% | -24.39% | — | |
| $0.07 | $30.66M | -0.17 | -31.57% | -356.89% | — | — | |
| $3.02 | $329.76M | -1.50 | — | — | -5.76% | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — |
Solid Biosciences Inc. (SLDB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Solid Biosciences Inc. (SLDB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 10, 2026·SEC
Apr 10, 2026·SEC
Get notified when SLDB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Solid Biosciences Inc. (SLDB) stock FAQ — growth, dividends, profitability & financials explained
Solid Biosciences Inc. (SLDB) reported a net loss of $207.1M for fiscal year 2025.
Solid Biosciences Inc. (SLDB) has a return on equity (ROE) of -109.9%. Negative ROE indicates the company is unprofitable.
Solid Biosciences Inc. (SLDB) had negative free cash flow of $187.8M in fiscal year 2025, likely due to heavy capital investments.
